GRN and frontotemporal dementia: In this interim analysis of the open-label phase 1/2 trial in patients with FTD-GRN, treatment with PR006 was generally safe and well tolerated and increased CSF progranulin and urinary levels of BMP, a functional readout potentially indicative of pharmacological efficacy at the lysosomal level.